Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about tACS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| EC layer II SST interneurons | inhibits | cell_type | 0.90 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Closed-loop tACS targeting EC-II parvalbumin interneurons to | 0.869 | Alzheimer's disease | Circuit-level neural dynamics in neurode |
| Selective APOE4 Degradation via Proteolysis Targeting Chimer | 0.795 | neurodegeneration | APOE4 structural biology and therapeutic |
| Closed-loop tACS targeting EC-II PV interneurons to suppress | 0.788 | Alzheimer's disease | Circuit-level neural dynamics in neurode |
| Closed-loop tACS targeting entorhinal cortex layer II SST in | 0.784 | Alzheimer's disease | Circuit-level neural dynamics in neurode |
| Closed-loop tACS targeting EC-II SST interneurons to block t | 0.722 | Alzheimer's disease | Circuit-level neural dynamics in neurode |
| Closed-loop tACS targeting EC-II PV interneurons to enhance | 0.596 | Alzheimer's disease | Circuit-level neural dynamics in neurode |
| Closed-loop tACS targeting EC-II somatostatin interneurons t | 0.564 | Alzheimer's disease | Circuit-level neural dynamics in neurode |
Scientific analyses that reference this entity
neuroscience | 2026-04-03 | 73 hypotheses Top: 0.968
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| GWAS of plasma NfL in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma pTau217 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| Dairy intake and dementia risk in Malmö Diet and Cancer cohort | clinical | Alzheimer's disease | 0.950 | 0.00 | Swedish community-based adults | proposed | N/A |
| GWAS of plasma pTau181 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma GFAP in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| KEEPS Continuation: Long-term effects of menopausal hormone therapy on | clinical | Alzheimer's disease | 0.950 | 0.00 | recently menopausal women with | proposed | N/A |
| GWAS of composite biomarker score | exploratory | Alzheimer's disease | 0.900 | 0.00 | human patients - East Asian co | proposed | N/A |
| RBG treatment in ApoE-/- atherosclerosis mouse model | validation | atherosclerosis | 0.900 | 0.00 | ApoE-/- mice | proposed | N/A |
| s:** - Biochemical binding assays measuring PROTAC selectivity for APO | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| Why Does Amyloid Removal Only Slow Decline 27%? — Mechanistic investig | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] | Litvinchuk A, Suh JH, Guo JL, Lin K, Dav | Neuron | 2024 | 1 |
| The cell biology of APOE in the brain. [PMID:37805344] | Windham IA, Cohen S | Trends Cell Biol | 2024 | 1 |
| The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] | Maxine R Nelson, Peng Liu, Ayushi Agrawa | Nature neuroscience | 2023 | 1 |
| APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] | Serrano-Pozo A, Das S, Hyman BT | Lancet Neurol | 2021 | 1 |
| Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] | Banik SM, Pedram K, Wisnovsky S, Ahn G, | Nature | 2020 | 1 |
| Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] | Long JM, Holtzman DM | Cell | 2019 | 1 |
| Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008] | Yamazaki Y, Zhao N, Caulfield TR, Liu CC | Nat Rev Neurol | 2019 | 1 |
| Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] | Cetindag AC, Schipke CG, Esselmann H, Kr | The journal of prevention of A | 2026 | 0 |
| Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] | Thedim M, Hu J, Maher M, Wiener-Kronish | Br J Anaesth | 2026 | 0 |
| Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] | Bae H, Song Z, Ali A, Sasaki T, Tesi N e | Geroscience | 2026 | 0 |
| Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] | Stern A, Linial M | Geroscience | 2026 | 0 |
| Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasi [PMID:40886963] | Zhu L, Du L, Wu J, Ding D, Wang J et al. | J Invest Dermatol | 2026 | 0 |
| Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsu [PMID:41101204] | Sang Y, Cao Y, Li S, Quan Y, Wang S et a | Biomaterials | 2026 | 0 |
| Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β path [PMID:41445196] | Lin Z, Xiong J, Zhang F, Zhang H, Zhu M | Mol Ther | 2026 | 0 |
| Menopause, cognition, and Alzheimer's disease risk. [PMID:41531227] | Samudra N, Vemuri M, Weitlauf J | Curr Opin Obstet Gynecol | 2026 | 0 |
| Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pa [PMID:41930593] | Yoshida K, Saito N, Takahashi R, Ando S, | J Alzheimers Dis | 2026 | 0 |
| UBE2I Alleviates Pyroptosis in Coronary Heart Disease by Promoting the SUMOylati [PMID:41930933] | Ding SK | Immunol Invest | 2026 | 0 |
| Neuropsychiatric symptoms and apolipoprotein E genotypes in neurocognitive disor [PMID:40145985] | Lozupone M, Leccisotti I, Mollica A, Ber | Neural regeneration research | 2026 | 0 |
| Cognitive Decline and Neurodegenerative Markers in Psoriasis: The Role of APOE4 [PMID:41912201] | Sabry HH, Kadhum BQ, Abdulmohsin GN, El- | Dermatology practical & concep | 2026 | 0 |
| Association of Periodontal Pathogens and Their Inflammatory Mediators With Alzhe [PMID:41890452] | Arriaga P, Vianna K, Montez C, Panariell | Cureus | 2026 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 6 · Score: 0.95 · 2026-04-27
closed · Rounds: 6 · Score: 0.95 · 2026-04-27
closed · Rounds: 4 · Score: 0.65 · 2026-04-27
closed · Rounds: 4 · Score: 0.71 · 2026-04-27
closed · Rounds: 4 · Score: 0.87 · 2026-04-27
closed · Rounds: 4 · Score: 0.48 · 2026-04-27
closed · Rounds: 4 · Score: 0.54 · 2026-04-27
closed · Rounds: 4 · Score: 0.19 · 2026-04-27
closed · Rounds: 4 · Score: 0.40 · 2026-04-27
closed · Rounds: 4 · Score: 0.50 · 2026-04-27
Hypotheses and analyses mentioning tACS in their description or question text
Score: 0.596 · Alzheimer's disease · 2026-04-07
## Mechanistic Overview Closed-loop tACS targeting EC-II PV interneurons to enhance perisomatic inhibition and block tau
Score: 0.564 · Alzheimer's disease · 2026-04-20
## Mechanistic Overview Closed-loop tACS targeting EC-II somatostatin interneurons to restore dendritic integration and